Novo Nordisk’s Wegovy helps free 40% of kids from obesity in phase 3 trial

Novo Nordisk has reported a phase 3 weight-management win for Wegovy in children, with two out of five kids no longer classified as having obesity after receiving the GLP-1 drug for 68 weeks.